TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of ultra-processed foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean VAS rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MIDAS questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Yo-Yo Intermittent Recovery Level 1 test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal pulmonary oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of opioid-positive tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emPHasis-10 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EuroQol-5D VAS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: WOMAC-pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Post-ERCP Pancreatitis (PEP)
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of S. mutans associated with high risk of developing tooth decay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque Index (PI) trend over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine hyporesponsiveness for Spike IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vaccine hyporesponsiveness for Spike-ACE2-receptor-blocking antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lack of durable response for Spike IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lack of durable response for Spike-ACE2-receptor-blocking antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intraoral adjustments required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in impulsivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in eating-disorder psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of finding aberrant signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of finding aberrant signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in modified Neuropathy Impairment Score +7 (mNIS+7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean days of past 30-day alcohol or drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance from the suture line of hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wind-up ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: balance confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perceived fall risk
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: flexibility and posture levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in risk of recurrence of low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dice score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HD95
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unwillingness to have a person with OUD marry into the family
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Warmth rating towards individuals with OUD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Unwillingness to have a person with OUD as a neighbor
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Reduced analgesic usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall anemia prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of mild anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of moderate/severe anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postdose reductions in aortic Zc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in monthly number of headache days of at least moderate severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving a ≥50% reduction in headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PGIC and HIT-6 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expression levels of serum TGF‐β1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of cystatin C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGM sensor glucose drift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Two-hour postprandial (2hpp) glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fall hazard
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical recovery rates of NIHSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall errors in fixture installations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disgust acceptance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ERP refusal rate
Endpoint domain: Adverse events/effects
Primary endpoint: Complete resolution of peri-implant mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of peri-implant mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in average BOP-positive sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implementation or expansion of POCT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean VO2max increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean apoB/apoA‐I ratio decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single-limb standing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IVCCI measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: monthly average migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body weight reduction of at least 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Loss to Follow-Up (LTFU)
Endpoint domain: Mortality/survival
Primary endpoint: tendon repair integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preservation of lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein partition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant reduction in anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total hospital bed days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Median cost of inpatient care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Nasal high-flow treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Impression cytology grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DMBT1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nocturnal coughs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-stent restenosis (ISR) prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median time to wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of healing (mm/d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in BVAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in eosinophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: NPI-NH score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to BVM initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Hb values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants achieving target Hb levels (10.0-12.0 g/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of postpartum depression
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in disease risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-management ability scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: shoulder amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: emotional processing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mood ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Urinary continence recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive surgical margins (PSM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical course of patients with RHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean horizontal bone width after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean primary stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean secondary stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mNIS+7Ionis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Norfolk QOL-DN
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: JTT score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FNT score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Hamilton depression scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in self‐rating idea of suicide scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WORC scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Endostatin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hip function measured using the Harris Hip Score (HHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse events recorded
Endpoint domain: Adverse events/effects
Primary endpoint: Budget impact
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Posterior wall injury rate
Endpoint domain: Adverse events/effects
Primary endpoint: Cholecystokinin release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average sample size
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Antidepressant adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total cardiac costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cessation of convulsive status epilepticus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Time to convulsive status epilepticus cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of serious adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of high-grade squamous intraepithelial lesions (HSIL) or cervical cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CR% (Complete Response Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: EBVDNA clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of acute toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: FeO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in liver fat fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with ≥20% reduction from baseline GE t1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Attitude toward fictional person
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-reported weekly walking minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily hours spent sitting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of adenosine diphosphate (ADP)‐induced platelet aggregation (%IPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: conversion from AS to definitive treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on edema formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate at 1 week after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late gadolinium enhancement as a percentage of the total left ventricular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of online ratings
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quantity of online ratings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean time taken to obtain a result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time away from the patient's bedside
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe pulmonary adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Possible pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: short-interval intracortical inhibition (SAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SCA-FD improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SF-NDI improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: DASS-21 improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in CRT (µm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deaths due to liver failure
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of ischemic hepatitis (IH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of viloxazine and lisdexamfetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of viloxazine and lisdexamfetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of viloxazine and lisdexamfetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BG control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vein degree improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient and nurse satisfaction levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of grade III to IV febrile neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Good marginal integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unnecessary referral rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Early detection of COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Early detection of CVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: occurrence of tachyarrhythmias after AMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intragastric pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Chronic Pain at rest (CPIP) after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 AUC0–12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: trough FEV1 on Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adjusted mean change in GLOESS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean hemoglobin level increment 2 weeks post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Estimated blood loss during delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: all-cause mortality, appropriate ICD shock, and VT storm
Endpoint domain: Mortality/survival
Primary endpoint: Stigmatizing attitudes toward patients with podoconiosis
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: patient reported disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: complete healing percentage for the lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients surviving to hospital discharge
Endpoint domain: Mortality/survival
Primary endpoint: Median organ support-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection rate at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean concentration at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative risk for death
Endpoint domain: Mortality/survival
Primary endpoint: Summary of Diabetes Self‐Care Activities general diet score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical Outcomes Study Short Form Health Survey mental component score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Healthy Eating Index 2015 total vegetable component score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Takotsubo syndrome following cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reliable improvements on relevant social cognitive measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: fracture displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loosening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of DGP-IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive-predictive value (PPV) of DGP-IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of DGP-IgG titer with enteropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lowest peripheral capillary oxygen saturation values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: need for interventions during treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Memory and learning of treatment contents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: study-drug interruption
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge about basic life support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychomotor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain in the recovery room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ibuprofen use at day two
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in knowledge, attitude, and performance of pregnant women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes